Business / Finance

RSS

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Prestige Brands Holdings, Inc. today announced results for the third quarter and nine months of fiscal year 2011, which ended on December 31, 2010. Following the close of the quarter, the Company completed the previously announced acquisition of the Dramamine® Brand in the U.S. from McNeil-PPC, Inc.

9 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011

DENTSPLY 2010 net sales increase 2.9% to record $2.221 billion

DENTSPLY International Inc. today announced sales and earnings for the three months and year ended December 31, 2010.

9 Feb 2011

Karo Bio fourth quarter net loss increases to MSEK 50.1

The January - December period and fourth quarter 2010 in brief

9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

Vitrolife fourth quarter sales increases 20% to SEK 81 million

A quarter with record sales concluded a year that set the stage for an increased potential in growth.

9 Feb 2011

Elan and Boehringer Ingelheim enter global collaboration for antibody-based therapeutics

Elan plc and Boehringer Ingelheim today announced that they have entered into a global technical development and manufacturing agreement for antibody-based therapeutics.

9 Feb 2011

Curaxis listed on Frankfurt Stock Exchange

Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp., today announced Curaxis' new listing on the Frankfurt Stock Exchange (FSE). Curaxis was at the FSE for its opening on February 8, 2011, and will trade under the symbol 8CX:GR.

9 Feb 2011

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

SwitchGear Genomics, BioCat enter distribution agreement for LightSwitch Luciferase Assay System in Europe

SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company signed an agreement for BioCat GmbH to distribute the innovative LightSwitch Luciferase Assay System™ in Europe.

9 Feb 2011

MRI Medical announces name change to Xeridiem Medical Devices

MRI Medical Inc. is changing its name to Xeridiem Medical Devices, Inc. as part of its corporate development plan.

9 Feb 2011

Kindred Healthcare signs definitive merger agreement to acquire RehabCare

Kindred Healthcare, and RehabCare Group, today jointly announced the signing of a definitive merger agreement under which Kindred will acquire RehabCare.

8 Feb 2011

Gizmox announces entry into Business Mobility Market

Gizmox, the developer of Visual WebGui Web & Cloud Platform, announced today their entrance into the Business Mobility Market. Visual WebGui's Instant CloudMove migration, which enables users to migrate client/server applications to the Web or Cloud, has now been extended to make business applications accessible from Mobile/Tablet devices using a simple mapping and configuration tool.

8 Feb 2011

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.

8 Feb 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2010.

8 Feb 2011

Almac opens analytical facility at new 240,000 sq. ft. North American Headquarters

Almac's new 240,000 sq. ft. North American Headquarters, built on 40 acres in Souderton, PA, north of Philadelphia is part of the Almac Group's integrated services solutions strategy. The new facility delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients.

8 Feb 2011

Kronos to acquire API Healthcare from Francisco

Kronos Incorporated today announced that it has entered into a definitive agreement to acquire API Healthcare Corporation from Francisco Partners. Closing of the transaction is subject to regulatory approval and customary closing conditions.

8 Feb 2011

EpiCept enters definitive agreements to purchase 8.9 million shares of common stock

EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 8.9 million shares of its common stock at $0.80 per share, and five-year warrants to purchase up to approximately 3.6 million shares of common stock at an exercise price of $0.75 per share.

8 Feb 2011

Business / Finance

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

DENTSPLY 2010 net sales increase 2.9% to record $2.221 billion

Karo Bio fourth quarter net loss increases to MSEK 50.1

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Vitrolife fourth quarter sales increases 20% to SEK 81 million

Elan and Boehringer Ingelheim enter global collaboration for antibody-based therapeutics

Curaxis listed on Frankfurt Stock Exchange

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

SwitchGear Genomics, BioCat enter distribution agreement for LightSwitch Luciferase Assay System in Europe

MRI Medical announces name change to Xeridiem Medical Devices

Kindred Healthcare signs definitive merger agreement to acquire RehabCare

Gizmox announces entry into Business Mobility Market

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

Elan 2010 total revenue increases 5% to $1,169.7 million

Teva fourth quarter net sales increase 16% to record $4.4 billion

Almac opens analytical facility at new 240,000 sq. ft. North American Headquarters

Kronos to acquire API Healthcare from Francisco

EpiCept enters definitive agreements to purchase 8.9 million shares of common stock

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News